Immunotoxicity has emerged as a key health concern for per- and polyfluoroalkyl substances (PFAS), with animal studies showing reduced T-dependent antibody responses (TDAR) and epidemiological studies reporting decreased vaccine antibody titres. Notably, immunotoxicity is considered one of the most sensitive endpoints for PFAS exposure and has been used to inform regulatory guidance and health-based values. Given that more tha...